FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

FDA Approves Lurbinectedin/Atezolizumab for ES-SCLC Maintenance | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

The FDA approves lurbinectedin and atezolizumab for first-line maintenance in extensive-stage small cell lung cancer, enhancing survival rates significantly.

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

– Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal Phase III IMforte study – – First and only combination therapy for the first-line maintenance treatment of ES-SCLC, which is critical to help address the high rate of relapse in ES-SCLC – – Regimen recommended in National Comprehensive Cancer Network® Guidelines for SCLC* – SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of…